Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
6(100.0%)
6Total
N/A(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01318486Not ApplicableCompleted

HepZero:Heparin Free Dialysis With Evodial

Role: collaborator

NCT00781690Not ApplicableCompleted

Reduction of Heparin Dose in Dialysis With Evodial System

Role: collaborator

NCT00614146Not ApplicableCompleted

Recompensation of Exacerbated Liver Insufficiency With Hyperbilirubinemia and/or Encephalopathy and/or Renal Failure

Role: collaborator

NCT01783626Not ApplicableCompleted

Evaluation of Evodial Hemodialyzer Selectivity Modifications (Evodial +)

Role: collaborator

NCT00804453Not ApplicableCompleted

Evaluation of the Biocompatibility of Cartridge Blood Set Versus Standard Blood Line

Role: collaborator

NCT00922870Not ApplicableCompleted

Evaluation of Hemodynamic Effects of Cascade Hemofiltration in Septic Shock

Role: collaborator

All 6 trials loaded